Antibe Therapeutics Inc. (OTCMKTS:ATBPD – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $0.22 and last traded at $0.22, with a volume of 0 shares changing hands. The stock had previously closed at $0.22.
Antibe Therapeutics Stock Performance
The company has a market capitalization of $83.44 million, a price-to-earnings ratio of -0.36 and a beta of 0.57. The firm has a fifty day moving average price of $0.44 and a 200-day moving average price of $0.54.
About Antibe Therapeutics
Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.
See Also
- Five stocks we like better than Antibe Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Comprehensive PepsiCo Stock Analysis
- What Are Trending Stocks? Trending Stocks Explained
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
